Newly Diagnosed Diffuse Large B-Cell Lymphoma
GMABGenmabCatalyst overview
Research summary
This catalyst tracks a Phase 2/3 data readout for Epkinly/Epcoritamab (GEN3013) (CD3-CD20 Bispecific) + R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma. The expected timing is based on the latest available company guidance and may change.
07/23/26:- EPCORE DLBCL-2 epcoritamab plus R-CHOP data in newly diagnosed DLBCL anticipated in 2026.
Verification
Confirm timing and program details against the company announcement or filing.